Your browser doesn't support javascript.
loading
Proteogenomic landscape of gastric adenocarcinoma peritoneal metastases.
Zhao, Shuangtao; Wang, Ruiping; Song, Shumei; Hao, Dapeng; Han, Guangchun; Song, Xingzhi; Zhang, Jianhua; Pizzi, Melissa Pool; Shanbhag, Namita; Futreal, Andrew; Badgwell, Brian; Harada, Kazuto; Calin, George; Vykoukal, Jody; Yu, Chuan-Yih; Katayama, Hiroyuki; Hanash, Samir M; Wang, Linghua; Ajani, Jaffer A.
Afiliação
  • Zhao S; Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang R; Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Song S; GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hao D; Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Han G; Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Song X; Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhang J; Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Pizzi MP; GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Shanbhag N; GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Futreal A; Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Badgwell B; Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Harada K; GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Calin G; Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Vykoukal J; Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yu CY; Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Katayama H; Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hanash SM; Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang L; Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ajani JA; GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
iScience ; 26(6): 106913, 2023 Jun 16.
Article em En | MEDLINE | ID: mdl-37305699
ABSTRACT
Advanced gastric adenocarcinoma (GAC) often leads to peritoneal carcinomatosis (PC) and is associated with very poor outcome. Here we report the comprehensive proteogenomic study of ascites derived cells from a prospective GAC cohort (n = 26 patients with peritoneal carcinomatosis, PC). A total of 16,449 proteins were detected from whole cell extracts (TCEs). Unsupervised hierarchical clustering resulted in three distinct groups that reflected extent of enrichment in tumor cells. Integrated analysis revealed enriched biological pathways and notably, some druggable targets (cancer-testis antigens, kinases, and receptors) that could be exploited to develop effective therapies and/or tumor stratifications. Systematic comparison of expression levels of proteins and mRNAs revealed special expression patterns of key therapeutics target notably high mRNA and low protein expression of HAVCR2 (TIM-3), and low mRNA but high protein expression of cancer-testis antigens CTAGE1 and CTNNA2. These results inform strategies to target GAC vulnerabilities.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: IScience Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: IScience Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos